

## Special Issue

# Experimental Animal and Organoid-Based Lethal Virus Infection Models for Human, Companion Animals and Livestock

### Message from the Guest Editor

There are lethal viral infections in humans and animals. Some of these have no preventive or therapeutic agents. To overcome this problem, appropriate research models are needed. In fact, various in vitro and in vivo models have been established for the study of COVID-19, which was recognized as a global pandemic in 2020. In this Special Issue, we are looking for excellent research using organoids as in vitro models and experimental animals as in vivo models. In this special feature, we are looking for excellent research results using organoids and experimental animals. The content of the research is not limited, as long as it contributes to the elucidation of the pathogenesis of lethal viral infections and the development of vaccines and therapeutic drugs for humans, companion animals, and livestock.

### Guest Editor

Prof. Dr. Tomomi Takano

Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada 034-8628, Japan

### Deadline for manuscript submissions

31 December 2025



## Viruses

an Open Access Journal  
by MDPI

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/219481](https://mdpi.com/si/219481)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[viruses](https://viruses.mdpi.com)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).